<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676076</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-05993AB1-03</org_study_id>
    <secondary_id>2015-000716-18</secondary_id>
    <nct_id>NCT02676076</nct_id>
  </id_info>
  <brief_title>TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA</brief_title>
  <acronym>TRIMARAN</acronym>
  <official_title>A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 100/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN PATIENTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG ACTING ß2 AGONISTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the superiority of CHF 5993 100/6/12.5 µg pMDI
      (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus
      glycopyrronum bromide) versus CHF 1535 100/6 µg pMDI (fixed combination of extrafine
      beclometasone dipropionate plus formoterol fumarate), in terms of lung functions parameters
      and rate of exacerbations, as well as to assess its safety and some health economics
      outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose FEV1 (Forced Expiratory Volume in the first second)</measure>
    <time_frame>at Week 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction of moderate and severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak FEV1 (Peak of Forced Expiratory Volume in the first second) within 3 hours post-dose</measure>
    <time_frame>at Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in morning PEF (Peak Expiratory Flow)</measure>
    <time_frame>Week 0 to Week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of severe asthma exacerbations rate</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Pooled analysis of CCD-05993AB1-03 and CCD-05993AB2-02 trials</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events and Adverse Drug reactions</measure>
    <time_frame>Up to Week 52</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Collection of Health Economics outcomes</measure>
    <time_frame>Week 0 to Week 52</time_frame>
    <description>Total use of healthcare resources and absence from work</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1153</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment A:
CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF 1535 100/6 µg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment B :
CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 5993 100/6/12.5 µg</intervention_name>
    <arm_group_label>CHF 5993 100/6/12.5 µg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CHF 1535 100/6 µg</intervention_name>
    <arm_group_label>CHF 1535 100/6 µg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of asthma ≥ 1 year and diagnosed before 40 years old

          -  Uncontrolled asthma with double therapy only on medium doses of Inhaled CorticoSteroid
             (ICS) in combination with Long-acting beta2 Agonist (LABA) with ACQ-7 (Asthma Control
             Questionnaire) ≥1.5

          -  Pre-bronchodilator FEV1 &lt;80% of the predicted normal value

          -  Positive reversibility test

          -  At least 1 documented asthma exacerbation in the previous year

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks
             prior screening

          -  Current or ex-smokers (&gt;= 10 packs year)

          -  Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks
             prior screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Virchow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Facharzt für Innere Medizin Rostock, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiesi Clinical Trial Site 276814</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>asthma, anticholinergics, triple combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

